Back to top
more

Becton, Dickinson and Company (BDX)

(Delayed Data from NYSE)

$236.34 USD

236.34
1,326,411

-5.84 (-2.41%)

Updated Sep 4, 2024 03:57 PM ET

After-Market: $236.32 -0.02 (-0.01%) 5:34 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 31% (173 out of 251)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Based in Franklin Lakes, NJ, Becton, Dickinson and Company (BDX) commonly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. In fiscal 2019, BD’s revenues increased 8.2% to $17.29 billion. Earlier, BD’s operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. However, the company’s organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional.

Becton Dickinson (BDX) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates

by Zacks Equity Research

Evaluate the expected performance of Becton Dickinson (BDX) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

BD (BDX) Collaborates With Hamilton to Benefit Researchers

by Zacks Equity Research

Becton, Dickinson and Company (BDX) partners with Hamilton to boost its portfolio of single-cell multiomics solutions, enabling researchers to perform more confident experiments.

Earnings Preview: Becton Dickinson (BDX) Q1 Earnings Expected to Decline

by Zacks Equity Research

Becton Dickinson (BDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GameStop and Becton, Dickinson and Company have been highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

GameStop and Becton, Dickinson and Company are part of the Zacks Bull and Bear of the Day article.

David Bartosiak headshot

Bear of the Day: Becton, Dickenson and Co (BDX)

by David Bartosiak

Earnings have been retreating on this Bear of the Day.

New Strong Sell Stocks for December 11th

by Zacks Equity Research

DG, BDX and CIGI have been added to the Zacks Rank #5 (Strong Sell) List on December 11, 2023.

BD's (BDX) Novel Blood Collection System MiniDraw Gets FDA Nod

by Zacks Equity Research

BD's (BDX) FDA approval for MiniDraw will likely reshape diagnostic testing by providing a unique design that offers blood collection at any convenient location with reduced volume.

BD (BDX) Launches Advanced Vascular Access Management System

by Zacks Equity Research

BD's (BDX) SiteRite 9 Ultrasound System is likely to revolutionize vascular care by enhancing clinician efficiency and setting a new standard in first-attempt success.

BD (BDX) Q4 Earnings In-Line With Estimates, Margins Contract

by Zacks Equity Research

BD's (BDX) overall top line benefits from revenue growth in all its segments and both geographic regions in the fiscal fourth quarter.

Here's What Key Metrics Tell Us About Becton Dickinson (BDX) Q4 Earnings

by Zacks Equity Research

Although the revenue and EPS for Becton Dickinson (BDX) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Unlocking Q4 Potential of Becton Dickinson (BDX): Exploring Wall Street Estimates for Key Metrics

by Zacks Equity Research

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Becton Dickinson (BDX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2023.

BD (BDX) Gears Up for Q4 Earnings: What's in the Offing?

by Zacks Equity Research

Continued strength in BD's (BDX) Life Sciences segment's base business is expected to have benefited fiscal fourth-quarter sales.

Becton Dickinson (BDX) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Becton Dickinson (BDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Labcorp (LH) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Labcorp (LH) delivered earnings and revenue surprises of 0.30% and 2.14%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Conmed (CNMD) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Conmed (CNMD) delivered earnings and revenue surprises of 8.43% and 1.12%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

The Zacks Analyst Blog Highlights Apple, Amgen, Becton, Dickinson, UnitedHealth and Verisk

by Zacks Equity Research

Apple, Amgen, Becton, Dickinson, UnitedHealth and Verisk are included in this Analyst Blog.

Sheraz Mian headshot

Top Stock Reports for Apple, Amgen & Becton, Dickinson

by Sheraz Mian

Today's Research Daily features new research reports on 12 major stocks, including Apple Inc. (AAPL), Amgen Inc. (AMGN) and Becton, Dickinson and Company (BDX).

Here's Why You Should Hold BD (BDX) Stock in Your Portfolio

by Zacks Equity Research

BD's (BDX) slew of product launches raises optimism about the stock.

BD's (BDX) Tie-Up to Explore Flow Cytometry for Clinical Outcomes

by Zacks Equity Research

BD's (BDX) latest partnership is likely to accelerate the delivery of innovative personalized therapies to patients who need them the most.

AMN Healthcare (AMN) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

AMN Healthcare's (AMN) dismal results in all its segments led to a soft overall Q2 performance.

DaVita (DVA) Tops Q2 Earnings Estimates, Ups FY23 EPS View

by Zacks Equity Research

DaVita's (DVA) robust dialysis patient service drives its second-quarter performance.

BD (BDX) Q3 Earnings Surpass Estimates, Margins Contract

by Zacks Equity Research

BD's (BDX) overall top line benefits from revenue growth in the majority of its segments and both geographic regions in the fiscal third quarter.

Becton Dickinson (BDX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

Although the revenue and EPS for Becton Dickinson (BDX) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Becton Dickinson (BDX) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Becton Dickinson (BDX) delivered earnings and revenue surprises of 2.42% and 1%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Is a Surprise Coming for BD (BDX) This Earnings Season?

by Zacks Equity Research

BD (BDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.